Compare CVV & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | NSRX |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 38.9M |
| IPO Year | 2007 | N/A |
| Metric | CVV | NSRX |
|---|---|---|
| Price | $7.33 | $3.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 72.7K | 11.0K |
| Earning Date | 05-12-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,128,639.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 96.27 | N/A |
| 52 Week Low | $2.76 | $1.98 |
| 52 Week High | $8.76 | $9.99 |
| Indicator | CVV | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 50.48 |
| Support Level | $6.46 | $2.78 |
| Resistance Level | $8.47 | $3.60 |
| Average True Range (ATR) | 0.58 | 0.21 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 21.16 | 44.60 |
CVD Equipment Corp designs, develops, and manufactures a broad range of equipment used to develop and produce materials and coatings for the aerospace, compound semiconductor, semiconductor, aerospace, battery energy storage markets as well as industrial applications, and research. It currently conducts its business through two reportable segments: CVD Equipment, which designs and manufactures chemical vapor deposition, physical vapor transport and thermal process equipment; and SDC, which designs and manufactures ultra-high purity gas and chemical delivery control systems. Its target markets are aerospace & defense and industrial, microelectronics / high power electronics, and EV battery materials / energy storage.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.